Colgate-Palmolive Company: Q1 2025 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Colgate-Palmolive Company for the period ended March 31, 2025. The Company operates in two primary segments: Oral, Personal and Home Care, and Pet Nutrition (Hill's). Approximately two-thirds of net sales are generated outside the U.S., with significant exposure to emerging markets. The Company recently announced the acquisition of the Prime100 pet food brand, expected to close in Q2 2025.
Key Financial Metrics
| Metric ($ Millions) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $4,911 | $5,065 |
| Gross Profit | $2,987 | $3,039 |
| Operating Profit | $1,076 | $1,047 |
| Net Income (Attributable to Colgate) | $690 | $683 |
| Diluted EPS | $0.85 | $0.83 |
| Operating Cash Flow | $600 | $681 |
| Total Debt | $8,269 | $7,949 (Dec 31, 2024) |
| Cash and Equivalents | $1,112 | $1,096 (Dec 31, 2024) |
Margins: Gross profit margin increased to 60.8% (from 60.0%); Operating profit margin increased to 21.9% (from 20.7%).
Material Changes vs. Prior Period
- Sales Performance: Net sales declined 3.1% year-over-year due to a 4.4% negative foreign exchange impact and a 0.1% volume decline, partially offset by 1.5% price increases. However, organic sales growth (excluding FX, acquisitions, and divestitures) increased 1.4%.
- Profitability: Operating profit rose 3% to $1,076 million. On a non-GAAP basis (excluding litigation and restructuring charges), operating profit increased 1%.
- Segment Highlights:
- Pet Nutrition: Sales up 1.5%; Operating profit up 30% to $258 million, driven by pricing and cost savings.
- Latin America: Sales down 8.7% (heavily impacted by FX), but organic sales grew 4.0%.
- North America: Sales down 3.6%; Organic sales declined 3.0% due to weakness in Personal and Home Care.
- Unusual Items: Q1 2025 included a $65 million pre-tax charge related to an ERISA litigation matter. Q1 2024 included $36 million in charges related to the 2022 Global Productivity Initiative.
Guidance, Outlook, and Risks
- Outlook: Management expects challenging global macroeconomic conditions, including inflation, high interest rates, and foreign currency volatility. The Company estimates incremental gross costs of approximately $200 million in 2025 due to new U.S. tariffs on imports from various countries (including China).
- Capital Allocation: The quarterly dividend was increased to $0.52 per share. The Board authorized a new $5 billion share repurchase program in March 2025, replacing the prior program.
- Risks and Contingencies:
- Legal: Ongoing talcum powder litigation (350 cases pending as of March 31, 2025) and Brazilian tax proceedings (potential exposure up to $101 million).
- Geopolitical: Continued monitoring of the war in Ukraine and Middle East conflict impacts on supply chains and costs.
- Intangibles: One indefinite-lived trademark fair value exceeded carrying value by less than 20%, indicating potential impairment risk if conditions worsen.
Investor Verification Checklist
- Verify the impact of the $65 million ERISA litigation charge on pension obligations and future cash contributions.
- Monitor the execution of the new $5 billion share repurchase program and the timing of the Prime100 acquisition closing.
- Assess the trajectory of organic sales growth in North America, which declined 3.0% in Q1.
- Track the realization of the estimated $200 million in incremental costs from new tariffs and the Company's ability to pass these costs to consumers.
- Review updates on the Brazilian tax proceedings and talcum powder litigation settlements.